Endotoxin is one of 69 small molecule programs targeting Metabolic Syndrome. It is currently in Phase 2.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
190 competitors in Metabolic Syndrome
Zetia
Jardiance
Kineret
Topamax
Benicar
Genotropin
Comparator: Statins
Rimonabant
Berberine
Pioglitazone and Insulin
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details